NBIX · Company research
2 upcoming catalysts · 0 phase 2+ trials on file
View Stock opens Yahoo Finance. Prices and performance charts are provided there.
Neurocrine Biosciences expects to report results from its Phase 3 study of Osavampator (NBI-1065845) for Major depressive disorder (adjunctive) in the second half of 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Neurocrine Biosciences expects to report results from its Phase 3 study of Direclidine (NBI-1117568) for Schizophrenia in the second half of 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Neurocrine Biosciences presented data on CRENESSITY (crinecerfont) for Classic congenital adrenal hyperplasia at a medical meeting on Jun 15, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Explore reported politician transactions and public investor statements connected to NBIX.
View source-linked activity ↗No phase 2+ trials cached for this company.
No recent headlines on file.